A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening

Murphy, Caitlin C.; Sen, A. K.; Watson, Bianca; Gupta, Samir; Mayo, Helen; Singal, Amit G.

doi:10.1158/1055-9965.epi-19-0775

Cited by 14 publications

(22 citation statements)

References 78 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A FOB is a relatively objective laboratory test for the assessment of GI, although false-negative results have been a concern for physicians. 17,18 In this study, 57.4% of FOB-positive patients did not…”

Section: Discussionmentioning

confidence: 49%

“…This suggests that a more objective tool is needed to improve the diagnostic accuracy for GI. A FOB is a relatively objective laboratory test for the assessment of GI, although false‐negative results have been a concern for physicians 17,18 . In this study, 57.4% of FOB‐positive patients did not exhibit gastrointestinal symptoms, suggesting that FOB can assess previously undetectable GI in COVID‐19 patients.…”

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

“…Fourth, in rare instances, other factors may have contributed to UI in patients. Finally, repeated FOB tests17 would be helpful for increasing the chances of detecting GI in COVID-19 patients.In conclusion, our data provide insight into the benefits of FOB and UCT in regard to assessing GI and UI in COVID-19 patients.These simple and cost-effective measures are of value for all COVID-19 patients, and they are particularly valuable for individuals in underdeveloped regions and countries where molecular diagnosis resources are lacking.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Fecal occult blood and urinary cytology tests for rapid screening of inflammatory infection in the gastrointestinal and urological systems in patients with Coronavirus disease 2019

Cao

Chen

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Gastrointestinal infections (GI) and urological infections (UI) have not been fully addressed in COVID‐19 patients. We aimed to evaluate the values of routine fecal occult blood (FOB) test and urinary cytology test (UCT) for screening of GI and UI in COVID‐19 patients. Methods In this retrospective study, COVID‐19 patients without associated comorbidities were divided into FOB‐ or UCT‐positive or FOB‐ or UCT‐negative groups. Their clinical characteristics and laboratory findings were then compared. Results A total of 13.6% of patients (47 of 345) tested positive for FOB, and 57.4% (27 of 47) of these patients lacked gastrointestinal symptoms. A total of 30.1% of patients (104 of 345) exhibited gastrointestinal symptoms, and 38.0% (131 of 345) were positive for either FOB or gastrointestinal symptoms. FOB‐positive patients possessed significantly higher levels of C‐reactive protein and fewer lymphocytes than FOB‐negative patients. A total of 36.9% of patients (80 of 217) exhibited positive UCT, and 97.5% (78 of 80) of these patients possessed normal levels of serum markers for renal injuries. Significant differences in age and sex ratios were observed between the UCT‐positive and UCT‐negative groups, and 72.4% (42 of 58) of female patients over 60 years old were UCT‐positive. Conclusions Fecal occult blood test in combination with gastrointestinal symptoms could serve as a simple and useful screening approach for GI diagnoses for COVID‐19. Age and sex are risk factors for UI in COVID‐19 patients. UCT could be a sensitive tool for assessing early UI at a stage in which serum markers for renal injuries appear normal.

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Fecal occult blood and urinary cytology tests for rapid screening of inflammatory infection in the gastrointestinal and urological systems in patients with Coronavirus disease 2019

Cao

Chen

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Both the fecal immunochemical test (FIT) and the mSEPT9 assay have been used for the opportunistic screening of CRC with satisfactory levels of performance. 3 – 5 …”

Section: Introductionmentioning

confidence: 99%

Opportunistic screening and survival prediction of digestive cancers by the combination of blood mSEPT9 with protein markers

et al. 2020

View full text Add to dashboard Cite

Background: The early detection of digestive cancers and precancerous diseases remains a significant challenge. This study aimed to investigate the performance of the blood methylated SEPT9 ( mSEPT9) assay, and the combination of this assay with serum protein markers, in hospital-based opportunistic screening strategies for digestive cancers. Methods: Opportunistic screening was performed in the participating hospitals on outpatients and inpatients who met specific inclusion criteria. We recruited a total of 2030 subjects, including 764 cancer patients [291 colorectal cancer (CRC), 239 gastric cancer (GC), 106 esophageal cancer (EC), and 128 hepatocellular carcinoma (HCC)], 423 subjects with precancerous diseases, and 843 normal subjects. All samples were transported to an authenticated clinical laboratory where the mSEPT9 tests were performed. Results: When used separately, the mSEPT9 detected CRC, GC, EC, and HCC, with a sensitivity of 76.6% [area under the receiver operating characteristic curve (AUC) = 0.86)], 47.7% (AUC = 0.76), 42.6% (AUC = 0.69), and 76.7% (AUC = 0.85) and a specificity of 94.6%, 92.3%, 92.5%, and 87.7%, respectively. The mSEPT9 assay also had potent ability to discriminate cancer from non-cancer subjects. The combination of mSEPT9 with CEA, CA724, SNCG, or AFP significantly enhanced the sensitivity for CRC, GC, EC, and HCC to 86.4% (AUC = 0.99, specificity = 92.8%), 63.6% (AUC = 0.86, specificity = 91.1%), 71.3% (AUC = 0.81, specificity = 82.1%), and 83.3% (AUC = 0.93, specificity = 85.1%), respectively. The performance of the mSEPT9 assay was influenced by cancer stage, patient age, pathological types, and the location of cancer. We also identified that mSEPT9 was an independent risk factor and was a valuable predictor for the long-term survival of digestive cancer patients, with a hazard ratio of 2.84, 2.07, 1.88, and 2.45, for CRC, GC, EC, and HCC, respectively. Conclusion: The blood mSEPT9 assay, whether used alone or in combination with serum protein markers, is effective for the opportunistic screening of digestive cancers. Furthermore, mSEPT9 is an independent risk factor and a predictive marker for the long-term survival of digestive cancer patients.

show abstract

Longitudinal adherence to annual colorectal cancer screening among Black persons living in the United States enrolled in a community‐based randomized trial

Arevalo,

Sutton,

Abdulla

et al. 2023

Cancer

View full text Add to dashboard Cite

BackgroundThis study examined repeat colorectal cancer screening rates at 12 and 24 months as part of a randomized intervention trial among Black persons living in the United States and factors associated with screening adherence.MethodsParticipants completed a survey assessing demographics and Preventive Health Model (PHM) factors (e.g., self efficacy, susceptibility) and received either a culturally targeted photonovella plus free fecal immunochemical test (FIT) kits (intervention group) or a standard educational brochure plus free FIT kits (comparison group). FIT return was assessed at 6, 12, and 24 months. Descriptive statistics summarized patterns of repeat screening. Logistic regression models assessed FIT uptake overtime, and demographic and PHM factors associated with screening adherence.ResultsParticipants (N = 330) were U.S.‐born (93%), non‐Hispanic (97%), and male (52%). Initial FIT uptake within 6 months of enrollment was 86.6%, and subsequently dropped to 54.5% at 12 months and 36.6% at 24 months. Higher FIT return rates were observed for the brochure group at 24 months (51.5% vs 33.3% photonovella, p = .023). Multiple patterns of FIT kit return were observed: 37% completed FIT at all three time points (full adherence), 22% completed two of three (partial adherence), 29% completed one of three (partial adherence), and 12% did not return any FIT kits (complete nonadherence). Predictors of full adherence were higher levels of education and self‐efficacy.ConclusionsFull adherence to repeat screening was suboptimal. Most participants had partial adherence (one or two of three) to annual FIT screening. Future studies should focus on strategies to support repeat FIT screening.

show abstract

A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening

Cited by 14 publications

References 78 publications

Fecal occult blood and urinary cytology tests for rapid screening of inflammatory infection in the gastrointestinal and urological systems in patients with Coronavirus disease 2019

Fecal occult blood and urinary cytology tests for rapid screening of inflammatory infection in the gastrointestinal and urological systems in patients with Coronavirus disease 2019

Opportunistic screening and survival prediction of digestive cancers by the combination of blood mSEPT9 with protein markers

Longitudinal adherence to annual colorectal cancer screening among Black persons living in the United States enrolled in a community‐based randomized trial

Contact Info

Product

Resources

About